Vicore Pharma (Buy, TP: SEK41.00) - Early but ATTRACTive results
Vicore reported positive results from the ATTRACT study in patients with Covid-19, with statistical significance on the clinical endpoint of reducing the risk of needing oxygen. No effect was shown on the primary endpoint, but we view this as less important as the SoC has changed, making CRP less relevant. We believe the results should be interpreted as promising, but in need of further study. Vicore plans to initiate a pivotal phase III study, which in our view will need additional funding.Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.